- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Harmony Biosciences Acknowledges U.S. Food & Drug Administration (FDA) Action Denying The Citizen Petition For WAKIX (pitolisant) | 61 | PR Newswire | FDA confirms the favorable benefit-risk profile of WAKIX
Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product... ► Artikel lesen | |
| 24.06. | Harmony Biosciences Receives U.S. Food And Drug Administration Approval For Wakix (pitolisant) In Pediatric Patients With Narcolepsy | 81 | PR Newswire | PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application... ► Artikel lesen | |
| 21.06. | A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts | 3 | Benzinga.com | ||
| 21.06. | Harmony Bio gains as Citi starts at Buy on risk-reward setup | 2 | Seeking Alpha | ||
| 18.06. | DelveInsight Business Research, LLP: Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Biosciences | 640 | PR Newswire | The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be further influenced by the extensive pipeline... ► Artikel lesen | |
| 05.06. | Harmony Biosciences Presents Positive Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1 | 52 | PR Newswire | PLYMOUTH MEETING, Pa., June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness... ► Artikel lesen | |
| 29.05. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View | 2 | Benzinga.com | ||
| 30.04. | Harmony Biosciences Holdings Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 30.04. | Key Takeaways From Harmony Biosciences Analyst Ratings | 1 | Benzinga.com | ||
| 30.04. | Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline | 2 | Seeking Alpha | ||
| 30.04. | Harmony Biosciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M | 2 | Seeking Alpha | ||
| 30.04. | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | 127 | GlobeNewswire (Europe) | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen | |
| 30.04. | Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | 122 | PR Newswire | Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase... ► Artikel lesen | |
| 29.04. | Harmony Biosciences Q1 2024 Earnings Preview | 1 | Seeking Alpha | ||
| 11.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.04. | Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist | 133 | PR Newswire | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,662 | -17,87 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 28.06.2024 - 1 | The following instruments on XETRA do have their last trading day on 28.06.2024.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 28.06.2024.ISIN Name DE000A37FT41 Epigenomics AG ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,000 | 0,00 % | Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-112? | ||
| MAINZ BIOMED | 0,362 | -0,82 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Unternehmensupdate nach dem ersten Halbjahr 2024 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Halbjahresergebnis
Mainz Biomed gibt Unternehmensupdate nach dem ersten Halbjahr 2024
02.07.2024 / 14:01 CET/CEST
Für... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,540 | +2,27 % | EQS-News: Defence Therapeutics Inc.: AccuTOX von Defence verstärkt die Wirkung von Immuncheckpointinhibitoren und schafft so Synergieeffekte | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 127,85 | -0,35 % | Neurocrine's NDA For Crinecerfont To Treat Congenital Adrenal Hyperplasia Gets Priority Review | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) Monday said the Food and Drug Administration or FDA has granted priority reviews for the company's two New Drug Applications for crinecerfont... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 48,270 | +1,51 % | How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin | ||
| GINKGO BIOWORKS | 0,320 | +1,27 % | Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan | DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,080 | -1,70 % | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) | CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the... ► Artikel lesen | |
| ARGENX | 402,40 | +0,15 % | Empasiprubart by Argenx for Multifocal Motor Neuropathy: Likelihood of Approval | ||
| RECURSION PHARMACEUTICALS | 7,320 | -0,41 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,960 | -0,52 % | Oncolytics Biotech Inc.: Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program | Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer
On track to report overall survival results from the randomized... ► Artikel lesen | |
| ARDELYX | 4,903 | +0,39 % | US Ardelyx, Eli Lilly, Tesla | ||
| ASSERTIO | 1,440 | +5,88 % | H.C. Wainwright starts Assertio at buy, calls stock underrated, overlooked | ||
| ARCTURUS THERAPEUTICS | 21,450 | -2,19 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,515 | -2,80 % | Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 | - Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST -
Vir Biotechnology... ► Artikel lesen |
HARMONY BIOSCIENCES HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,88 % bei einem Aktienkurs von 31,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HARMONY BIOSCIENCES HOLDINGS INC finden Sie auf Wallstreet Online.
